Bifunctional Molecules for MIF and IgG Degradation via ASGPr
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug development strategies for targeting macrophage migration inhibitory factor (MIF) and immunoglobulin G (IgG) face challenges such as low oral bioavailability, immunogenicity, and high cost, and traditional antibody-based approaches do not effectively eliminate these proteins, necessitating a more robust therapeutic approach.
Innovation Solution
Development of bifunctional small molecules that bind to MIF or IgG and engage the hepatocyte asialoglycoprotein receptor (ASGPr), leading to the degradation of these proteins within hepatocytes, thereby reducing their levels in circulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibody-based approaches are used to target MIF or IgG, then these proteins can be inhibited, but they cannot be effectively eliminated and the treatment lacks lasting effect
Solution Approach 1:
The patent introduces a bifunctional molecule as an intermediary that bridges the target protein (MIF or IgG) and the hepatocyte ASGPr degradation pathway. This intermediary molecule contains both a target protein binding domain and an ASGPr binding domain, enabling the recruitment of circulating proteins to hepatocytes for lysosomal degradation, thereby achieving elimination rather than just inhibition
Solution Approach 2:
The patent exploits the natural ASGPr degradation pathway, which normally handles asialoglycoproteins, and converts it into a therapeutic benefit by hijacking this pathway to degrade disease-causing proteins (MIF or IgG). The existing cellular machinery is repurposed to eliminate harmful proteins, turning a normal physiological pathway into a therapeutic weapon
2Reliability
If MIF or IgG levels are reduced through degradation, then disease symptoms are attenuated, but the complexity of the bifunctional molecule increases
Solution Approach 1:
The patent merges two distinct functional domains into a single bifunctional molecule: a target protein binding domain (anti-MIF or anti-IgG) and an ASGPr binding domain. This consolidation allows one molecule to perform dual functions - binding the target protein and directing it to hepatocytes for degradation - simplifying the overall therapeutic approach despite the increased molecular complexity
Solution Approach 2:
The bifunctional molecule is designed with universal applicability by combining a variable target protein binding domain with a fixed ASGPr binding domain. This modular design allows the same platform to target different proteins (MIF, IgG, or others) by simply changing the target binding domain, making the approach universally applicable to multiple disease states
3Ease of manufacture
If bifunctional molecules are used to degrade proteins, then manufacturing costs are reduced compared to antibodies, but the precision of protein elimination must be optimized
Solution Approach 1:
The bifunctional molecule exhibits local quality through its modular structure: the ASG_pr binding domain provides highly specific localization to hepatocytes via the ASGPr receptor, while the target protein binding domain provides specificity for the desired protein (MIF or IgG). This localized specificity at different binding sites ensures selective degradation only in the intended target tissue, optimizing manufacturing precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional molecules effectively lower MIF or IgG levels, potentially attenuating disease symptoms and providing a more lasting therapeutic effect compared to inhibition alone, with reduced side effects and lower manufacturing costs.
Implementation Method 1
the other end of the bifunctional molecule is a motif that binds to hepatocyte asialoglycoprotein receptor (ASGPr)
Implementation Method 2
binds to hepatocyte asialoglycoprotein receptor (ASGPr), which is a triantennary N-acetylgalactosamine
Implementation Method 3
selectively bind to MIF or IgG in circulation and form a protein complex
Implementation Method 4
When this protein complex passes through the liver, the asialoglycoprotein receptor binding moiety of the molecule will engage the endo-lysosomal pathway of hepatocytes
Implementation Method 5
MIF or IgG is eliminated from circulation by hepatocytes
Data Source
AI summary
Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Further described herein is a method for treating disease states and/or conditions with the compounds or the composition. The disease states and/or conditions are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, such as autoimmune diseases and cancer, among others.